The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014)

Table 2 GPELF MDA treatments (2000–2014)

WHO region	GPELF countries (2000–2014)^a	Pre-control number at-risk of infection (millions)^b	Minimum number treated 2000–2014 (millions)^c
AMRO	Brazil, Dominican Republic, Guyana, Haiti.	14	10
AFRO	Benin, Burkina Faso, Cameroon, Central African Republic, Comoros, Congo, Côte d’Ivoire, Democratic Republic of Congo, Ethiopia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mozambique, Niger, Nigeria, Senegal, Sierra Leone, Tanzania (incl. Zanzibar), Togo, Uganda.	425	191
EMRO	Egypt, Sudan Yemen.	23	3
WPRO	American Samoa, Brunei Darussalam, Cambodia, Cook Islands, Fed. States of Micronesia, Fiji, French Polynesia, Kiribati, Lao PDR, Marshall Islands, Malaysia, Niue, Papua New Guinea, Philippines, Samoa, Tonga, Tuvalu, Vanuatu, Vietnam, Wallis and Futuna.	45	24
SEARO	Bangladesh, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste.	902	536
All Regions	61 countries in total ^d	1409	763

AMRO Region of the Americas, AFRO African Region, EMRO Eastern Mediterranean Region, WPRO Western Pacific Region, SEARO South-East Asia Region
^aCountries that started since 2007 are indicated in bold
^bData taken from [5, 6]
^cA conservative approach was taken and the number of uniquely treated individuals in any one country was assumed to be the maximum number of individuals treated in any single MDA for each country
^d Palau has passed the TAS survey but never started MDA so is not included

ISSN: 2049-9957